No. As of September 2026, ipamorelin is not approved by the FDA for any medical indication in the United States. It is approved nowhere else either, and its Phase 2 programme for postoperative ileus was discontinued without an approval. Ipamorelin acetate remains on FDA's Category 2 list of bulk substances that may present significant safety risks, FDA's Pharmacy Compounding Advisory Committee voted 0–12 against it in October 2024, and WADA prohibits it at all times.
The table below shows ipamorelin's position on the five registers that decide whether a compound is approved, compoundable or prohibited in sport, and each row carries the as-of date its Peptigrity source gives.
Register | Ipamorelin's position | As of (Peptigrity source) |
|---|---|---|
FDA approval | Not approved for any medical indication, and never approved. The Phase 2 programme for postoperative ileus, run by Helsinn Therapeutics, was discontinued, and no other clinical programme is currently advancing. | August 2026 — ipamorelin compound page (as of August 2026) |
FDA Category 2 bulk list | Listed. Ipamorelin acetate was added to Category 2 on 29 September 2023, on immunogenicity and aggregation grounds, and remains on FDA's active list; it did not move off the list in April 2026. | FDA page current 22 April 2026 — FDA regulation timeline; compound page as of August 2026 |
PCAC review | Voted against. On 29 October 2024 the Pharmacy Compounding Advisory Committee voted on ipamorelin free base and acetate: 0 in favour, 12 against, 1 abstention on both. Ipamorelin was not on the 23–24 July 2026 agenda. | Vote of 29 October 2024 — FDA regulation timeline (as of August 2026) |
WADA | Prohibited at all times as a growth-hormone secretagogue under section S2.2.4, classified as non-specified. | WADA 2026 Prohibited List — compound page and ipamorelin vs sermorelin vs tesamorelin |
Other jurisdictions | Not approved anywhere. Ipamorelin is not approved for any medical indication anywhere in the world. | As of August 2026 — compound page |
Do you need a prescription for ipamorelin?
There is no prescription route to need. A prescription presupposes an approved drug, and ipamorelin has never been approved. The compounding route is closed as well: a bulk substance used in 503A compounding must comply with a USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulks list, and ipamorelin has no monograph, is not a component of an approved drug and sits on FDA's active Category 2 list.
That leaves research-grade material sold by third-party laboratories, which is not a lawful prescription route of any kind. This page states what published documents say. It is legal information, not legal advice, and anything touching your own circumstances belongs with a qualified professional.
What do Category 2 and the October 2024 vote mean for compounding?
They mean ipamorelin cannot be lawfully compounded. FDA's own definition is narrower than how it gets reported: a Category 2 substance was "nominated with sufficient supporting information to permit FDA to evaluate" it and "may be eligible for inclusion on the 503A bulks list," but FDA "has identified significant safety risks relating to the use of these substances in compounding pending further evaluation." A substance is not legally compoundable while it sits there.
The advisory vote pointed the same way. On 29 October 2024 the Pharmacy Compounding Advisory Committee returned 0 in favour, 12 against and 1 abstention on both ipamorelin free base and ipamorelin acetate. FDA's briefing document for that meeting records that "FDA has not identified data to support the effectiveness of ipamorelin… for the diagnosis or treatment of GHD," flags possible behavioural reinforcing properties and reproductive effects arising from ghrelin receptor agonism, and describes the free base as "not well-characterized from the physical and chemical characterization perspective."
Ipamorelin then stayed put while others moved. It remained on the active Category 2 list when FDA split its page into two tables in April 2026, and it was not on the July 2026 agenda that advanced BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. Not being reviewed is not the same as being rejected, and neither is the same as being cleared. The dated sequence is in the FDA regulation timeline for 2025–2026, and the statutory mechanics in compounding pharmacy versus research peptide.
Where does research-grade ipamorelin fit?
Ipamorelin is sold strictly as a research-use-only compound by third-party laboratories, and a research label does not change the regulatory position in FDA's view. The agency "has warned companies that have illegally sold unapproved drugs... falsely labeled 'for research purposes' or 'not for human consumption.' These products have been sold directly to consumers for human use." A warning letter dated 10 December 2024 applied that reasoning to a seller of research-labelled products, holding seven of them to be unapproved new drugs because website evidence established human intended use.
The enforcement in Peptigrity's record runs against sellers, and this page does not address the position of any purchaser. The wider market is described on the grey market overview.
What does "not FDA approved" mean for ipamorelin?
It means no regulator has assessed ipamorelin's safety or efficacy for marketing, so there is no label, no approved indication and no pharmacy route. The human record is short. Ipamorelin was developed by Novo Nordisk and reached Phase 2 trials for postoperative ileus; one randomised trial of 117 patients missed its endpoint, at 25.3 against 32.6 hours to a solid meal with p = 0.15, and a completed 320-patient Phase 2 trial, NCT01280344, never posted results. No Phase 3 efficacy trial for any indication has been published.
Approval is not in prospect either. No active clinical development programme for ipamorelin exists as of August 2026, and approval is unlikely without a renewed development effort by a pharmaceutical sponsor. In sport the answer is already settled: WADA names ipamorelin at S2.2.4 among growth-hormone secretagogues, prohibited at all times. Ipamorelin sits in the growth hormone category.
What does Peptigrity's lab record show for ipamorelin?
As of 21 September 2026, Peptigrity holds 436 independent lab tests of ipamorelin, averaging 99.67% HPLC purity (the average covers the 352 tests that report a purity figure), from 22 laboratories. Every result is listed on the ipamorelin lab tests page, with the compound record on the ipamorelin compound page, per-milligram prices on the ipamorelin price comparison and volume arithmetic in the ipamorelin calculator.
Read those figures for what they are. A purity percentage measures what is in a vial; it says nothing about legal status and nothing about the safety concerns FDA recorded. The certificates are ones shops chose to publish, a selection bias Peptigrity states openly.
Frequently Asked Questions
Is ipamorelin legal in the United States?
Ipamorelin is not approved for any medical indication, it cannot be lawfully compounded, and FDA has warned companies selling unapproved drugs labelled "for research purposes" to consumers for human use. The enforcement in Peptigrity's record runs against sellers; this page does not address any individual's legal position.
Do you need a prescription for ipamorelin?
No prescription route exists. A prescription presupposes an approved drug, and ipamorelin satisfies none of the three statutory prongs that would let a pharmacy compound it.
Will ipamorelin be FDA approved?
Not on the current record. No active clinical development programme exists as of August 2026, the Phase 2 postoperative-ileus programme was discontinued, and approval is unlikely without a renewed development effort by a pharmaceutical sponsor.
Is ipamorelin on FDA's Category 2 list?
Yes. Ipamorelin acetate was added on 29 September 2023 and remains on the active Category 2 list on FDA's page current 22 April 2026. Descriptions of ipamorelin "moving to Category 1" are inaccurate.
What did the FDA advisory committee decide about ipamorelin?
On 29 October 2024 the Pharmacy Compounding Advisory Committee voted 0 in favour, 12 against, with 1 abstention, on both ipamorelin free base and acetate. A committee vote is advisory; the operative fact is that ipamorelin remains on the active Category 2 list.
Is ipamorelin banned by WADA?
Yes. WADA's 2026 Prohibited List names ipamorelin at section S2.2.4 among growth-hormone secretagogues, prohibited at all times and classified as non-specified.
Sources
External documents cited on Peptigrity's own pages for the statements above.
FDA — Certain bulk drug substances for use in compounding that may present significant safety risks (page current 22 April 2026)
FDA — ipamorelin briefing document, Pharmacy Compounding Advisory Committee (October 2024)
Orrick — FDA announces removal of 12 peptides from Category 2 (nominations withdrawn) and schedules PCAC meetings (April 2026)
ClinicalTrials.gov — NCT00672074, ipamorelin for postoperative ileus (Phase 2)
WADA — Prohibited List (2026)
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Ipamorelin's status row, lab record and listings live on the ipamorelin compound page. How its position compares with other compounds, axis by axis and country by country, is in are peptides legal? Regulatory status by country.